Sobrevida a mediano plazo en los pacientes con hipertensión arterial pulmonar en la era de terapias vasodilatadoras específicas del territorio vascular pulmonar / Survival of patients with pulmonary arterial hypertension after the advent of specific pulmonary vasodilator therapies
Rev. méd. Chile
;
144(7): 829-836, jul. 2016. ilus, tab
Artículo
en Español
| LILACS
| ID: lil-793995
ABSTRACT
Background:
Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Long-term survival remains poor despite of advances in specific vasodilator therapy.Aim:
To describe the survival rate in a cohort of PAH patients in two referral centers in Chile. Patients andMethods:
One hundred fifteen patients aged 43 ± 15.6 years (85% females) with PAH qualified for this study. Their median pulmonary artery pressure was 55.4 ± 14 mmHg and their six minutes walking capacity was 368 ± 119 m. They were followed for 58 ± 0.4 months and their actual survival rates were compared with the estimated survival using the equation proposed by the French registry of PAH.Results:
One, two and three year survival rates were 97, 94 and 89%, respectively. The observed survival rates were greater than the estimated survival.Conclusions:
The improvement in survival rates observed in this cohort of patients is similar to what has been described in literature.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Vasodilatadores
/
Hipertensión Pulmonar
Tipo de estudio:
Estudio de etiología
/
Estudio de incidencia
/
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
País/Región como asunto:
America del Sur
/
Chile
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2016
Tipo del documento:
Artículo
País de afiliación:
Chile
Institución/País de afiliación:
Pontificia Universidad Católica de Chile/CL
Similares
MEDLINE
...
LILACS
LIS